# Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

> **NCT01818713** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 6 (estimated)

## Conditions studied

- Meningeal Carcinomatosis

## Interventions

- **DRUG:** 2B3-101

## Key facts

- **NCT ID:** NCT01818713
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818713, "Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01818713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*